Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.

protein a negative regulator of homologous recombination (HR), has been suggested to function as an oncogene in cervical, lung, and pancreatic cancer. OBJECTIVE:To investigate the expression profile of and its role in hepatocellular carcinoma (HCC). METHODS:Using data from the Cancer Genome Atlas and Human Protein Atlas databases, Pduanyu37BP expression level and its clinical implication in HCC were identified by t test and Chi-square test. The prognostic value of Pduanyu37BP in HCC was evaluated by Kaplan-Meier method, Cox regression analysis, and nomogram. Gene set enrichment analysis (GSEA) was used to screen biological pathways correlated with Pduanyu37BP expression in was significantly upregulated in HCC tissues compared with normal liver tissues (P < 0.05). High Pduanyu37BP expression was significantly associated with elevated serum AFP level, vascular invasion, poor tumor differentiation, and advanced TNM stage (all P < 0.05). Kaplan-Meier analyses suggested that upregulation of Pduanyu37BP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC. Multivariate analyses further confirmed that Pduanyu37BP upregulation was an independent indicator of poor OS and RFS (all P < 0.05). The prognostic nomograms based on Pduanyu37BP mRNA expression and TNM stage were superior to those based on the TNM staging system alone (all P < 0.05). Besides, Pduanyu37BP DNA copy gain and miR-139-5p downregulation were associated with Pduanyu37BP upregulation in HCC. GSEA revealed that "cell cycle," "HR," "DNA replication," and "p53 signaling" pathways were enriched in high Pduanyu37BP expression may be a promising prognostic biomarker and candidate therapeutic target in HCC.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}